SamiAir is the first FDA-approved COVID-19 therapeutic that achieves a 3-fold improvement in survival and recovery from respiratory failure in COVID-19, compared to best-available ICU care. It blocks replication of coronavirus in lung cells, blocks inflammatory cytokines, prevents death of lung cells, and increases oxygen exchange with the blood.
Market Data 
Markets 
AI
